ArticleFunctional & integrative genomics2023
Glycolysis induces Th2 cell infiltration and significantly affects prognosis and immunotherapy response to lung adenocarcinoma.
Article in Functional & integrative genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Mucosal immunity: mechanism and application in cancer immunotherapy.Journal of hematology & oncology · 2026Review
- tRNA-derived fragment AS-tDR-008272 promotes NSCLC tumorigenesis by propelling glycolytic metabolism via regulating HJURP.Translational oncology · 2026Article
- Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026Review
- DSG2+ Cancer Stem Cells Co-Located With FAP+ Myofibroblasts in the Tumor Boundary That Determines the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Observational
- Novel growth pattern-specific digital marker of TILs improves stratification of lung adenocarcinoma patients.The Journal of pathology · 2026Article
- Research hotspots and trends in lung cancer immunotherapy are revealed by a bibliometric study spanning the years 2004 to 2024.Human vaccines & immunotherapeutics · 2025Article
- Article
- Dual-targeted N-PMIMaterials today. Bio · 2025Article
- Integrated bioinformatics and experimental analysis of CHAF1B as a novel biomarker and immunotherapy target in LUAD.Discover oncology · 2025Article
- Assembly factor for spindle microtubules (Frontiers in genetics · 2025Article
- Serum pyruvate and lactate predict immunotherapy efficacy in advanced gastric cancer: a prospective biomarker study.Frontiers in immunology · 2025Observational
- Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer.International journal of biological sciences · 2025Review
- Long Non-Coding RNA LINC01116 Promotes the Proliferation of Lung Adenocarcinoma by Targeting miR-9-5p/CCNE1 Axis.Journal of cellular and molecular medicine · 2024Article
- Overexpression of CDCA8 predicts poor prognosis and drug insensitivity in lung adenocarcinoma.BMC medical genomics · 2024Article
- Roles of naïve CD4Journal of translational medicine · 2024Article
- The immune microenvironment of lung adenocarcinoma featured with ground-glass nodules.Thoracic cancer · 2024Review
- A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells.International journal of biological sciences · 2024Review
- Actors influencing cancer-related fatigue and the construction of a risk prediction model in lung cancer patients.Frontiers in oncology · 2024Article
- Forkhead box N1 is possibly a novel biomarker and prognostic indicator for patients with squamous cell lung carcinoma.International journal of medical sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glycolysis has a major role in cancer progression and can affect the tumor immune microenvironment, while its specific role in lung adenocarcinoma (LUAD) remains poorly studied. We obtained publicly available data from The Cancer Genome Atlas and Gene Expression Omnibus databases and used R software to analyze the specific role of glycolysis in LUAD. The Single Sample Gene Set Enrichment Analysis (ssGSEA) indicated a correlation between glycolysis and unfavorable clinical outcome, as well as a repression effect on the immunotherapy response of LUAD patients. Pathway enrichment analysis revealed a significant enrichment of MYC targets, epithelial-mesenchymal transition (EMT), hypoxia, G2M checkpoint, and mTORC1 signaling pathways in patients with higher activity of glycolysis. Immune infiltration analysis showed a higher infiltration of M0 and M1 macrophages in patients with elevated activity of glycolysis. Moreover, we developed a prognosis model based on six glycolysis-related genes, including DLGAP5, TOP2A, KIF20A, OIP5, HJURP, and ANLN. Both the training and validation cohorts demonstrated the high efficiency of prognostic prediction in this model, which identified that patients with high risk may have a poorer prognosis and lower sensitivity to immunotherapy. Additionally, we also found that Th2 cell infiltration may predict poorer survival and resistance to immunotherapy. The study indicated that glycolysis is significantly associated with poor prognosis in patients with LUAD and immunotherapy resistance, which might be partly dependent on the Th2 cell infiltration. Additionally, the signature comprised of six genes related to glycolysis showed promising predictive value for LUAD prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.